drugset
Drugs / SpFN_1B-06-PL
last change May 2024 re-read 3 minutes ago

SpFN_1B-06-PL

also known as SpFN

Vaccine

Developed for
COVID-19
Investigated by
Henry M. Jackson Foundation for the Advancement of Military Medicine · U.S. Army Medical Research and Development Command · Walter Reed Army Institute of Research (WRAIR)

Trials 1

today NCT04784767 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04784767 Apr 2021 → Mar 2023 COVID-19 U.S. Army Medical Research and Development Command Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SpFN_1B-06-PL ClinicalTrials.gov intervention name — accepted as the source's own label NCT04784767 ↗
Known as SpFN “A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl...” PMID 38761816 ↗ May 2024
Modality Vaccine “A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine” PMID 38761816 ↗ May 2024
Route Intramuscular “receive 25 μg or 50 μg of SpFN/ALFQ or saline placebo intramuscularly” PMID 38761816 ↗ May 2024